Previous 10 | Next 10 |
Gainers: ProQR Therapeutics (PRQR) +47%.Cellect Biotechnology (APOP) +47%.Houston Wire & Cable (HWCC) +38%.GameStop (GME) +29%.Koss (KOSS) +28%.Cinedigm (CIDM) +28%.F-star Therapeutics (FSTX) +26%.FreightCar America (RAIL) +24%.Polar Power (POLA) +20%.Immutep (IMMP) +20%.Losers:...
Shares of ProQR Therapeutics (PRQR) are up 36.8% to $7.77 in morning trading after Citi upgraded its price target from $33 to $44.Analyst Yigal Nochomovitz writes that the company should be worth ~$2B.Yesterday, ProQR announced positive results from a planned analysis of data from i...
Gainers: Cellect Biotechnology APOP +43%, ProQR Therapeutics (PRQR) +33%, Immutep Limited (IMMP) +29%, F-star Therapeutics (FSTX) +24%, Cancer Genetics CGIX +13%.Losers: Evolus EOLS -24%, Rite Aid RAD -24%, Evofem Biosciences (EVFM) ...
Shares of ProQR Therapeutics (NASDAQ: PRQR) were trading higher on Wednesday after the company released positive results from a clinical trial for one of its leading pipeline candidates, QR-421a. The biotech is also benefiting from bullish commentary from a Wall Street analyst. As o...
ProQR Therapeutics ([[PRQR]] +8.4%) has announced positive results from a planned analysis of data from its Phase 1/2 trial for QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.Based on the results, the company intend...
QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events reported Two pivotal Phase 2/3 trials are exp...
Gainers: [[MTRX]] +13.1%. [[DSWL]] +8.7%. [[STRO]] +6.9%. [[GIFI]] +3.3%. [[PRQR]] +3%.Losers: [[FHTX]] -6.8%. [[CRBP]] -3%. [[PRAX]] -2.8%. [[AAME]] -2.6%. [[BDSI]] -2.6%. For further details see: CRBP, BDSI, PRQR and MTRX among after-hours movers
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announ...
Today, we revisit ProQR Therapeutics for the first time since September. This Netherlands-based biotech concern is universally loved by analysts but isn't getting enough attention from investors, in my opinion. We update our investment thesis on this just under $5 biotech stock in...
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announ...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...